Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Interest Expenses (2020 - 2022)

Vivos Therapeutics has reported Interest Expenses over the past 3 years, most recently at $36000.0 for Q3 2022.

  • Quarterly Interest Expenses rose 300.0% to $36000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $36000.0 through Jun 2023, down 59.09% year-over-year, with the annual reading at $14000.0 for FY2021, 85.42% down from the prior year.
  • Interest Expenses was $36000.0 for Q3 2022 at Vivos Therapeutics, down from $37000.0 in the prior quarter.
  • Over five years, Interest Expenses peaked at $43723.0 in Q1 2020 and troughed at $1000.0 in Q1 2021.
  • The 3-year median for Interest Expenses is $17218.0 (2020), against an average of $20181.8.
  • Year-over-year, Interest Expenses plummeted 97.71% in 2021 and then soared 3700.0% in 2022.
  • A 3-year view of Interest Expenses shows it stood at $17218.0 in 2020, then plummeted by 76.77% to $4000.0 in 2021, then skyrocketed by 800.0% to $36000.0 in 2022.
  • Per Business Quant, the three most recent readings for VVOS's Interest Expenses are $36000.0 (Q3 2022), $37000.0 (Q2 2022), and $38000.0 (Q1 2022).